NZ IVF parents may get gender choice
By Brisbane Times,
Brisbane Times
| 06. 19. 2008
New Zealand parents involved in IVF programs could soon be allowed to choose the sex of their child if the government follows the advice of its Bioethics Council.
The council, a ministerial advisory committee, on Thursday handed the government a key report which said individuals were in the best position to make decisions about sex selection.
But the stance has drawn fire from the New Zealand Catholic Bioethics Centre, which said parenthood was not about "ordering" children to meet specifications.
The report - titled Who Gets Born? - says the gender of embryos created outside the mother's body under programs such as IVF should be chosen by parents, allowing them to gender-balance their families, The New Zealand Herald newspaper reported.
The council's recommendations relate specifically to pre-implantation genetic diagnosis, or PGD, when embryos are created outside the womb so they can be tested for likely inherited genetic conditions.
Under laws introduced in 2004, sex selection is banned in New Zealand except where it is part of treatment for a genetic disorder or disease.
It is also banned in Australia and...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...